From modest beginnings, the remarkable growth story of Actavis continues. Currently positioned among the world’s top five generic pharmaceutical companies, our ambition and performance remain consistently strong.
Our commitment to offering customers an exceptionally wide choice of high quality generics is clearly reflected in our development pipeline – one of the broadest in the industry. And our dynamic style ensures the timely delivery of trusted products, when and where they are needed.

Growing demand
Demand for generic pharmaceuticals is on the rise globally, independent of economic cycles. The company’s expertise in all aspects of product development is a central factor in Actavis’ success and we continue to exploit it fully as we further strengthen our position in our key markets in Europe, North-America and Asia. Building on our competitive strengths, we are also determined to enlarge our portfolio, enter new markets and secure all possible opportunities to reduce costs.
Considerable progress has been made in integrating recent acquisitions and we are reaping the benefits of the numerous synergies occurring throughout the company. Our customers, in turn, are able to take advantage of a fast-expanding and reliable global brand, fuelled by formidable organic growth.

Fast and flexible
A remarkable level of flexibility and a clear and well executed strategy have been part of the foundations for Actavis’ expansion, and those qualities of our business are here to stay.
Key to this agility is a truly phenomenal team of more than 11,000 people worldwide. With a mindset and determination that is probably unique in our field, we are immensely proud of what we have achieved and eager to raise the bar higher still.

Thank you

Sigurdur Oli Olafsson, CEO